Abstract
Simple SummaryHyperglycosylated cancer cells are often decorated with abundant sialic acids, which are recognized by Sialic acid binding immunoglobulin type lectins (Siglecs) expressed on immune cells. As sialic acids are normally expressed on almost all cell types, Siglecs can function as receptors for “self”. Presently, 15 human Siglecs (including non-sialic acid binding Siglec XII) are known, of which most are immunoinhibitory receptors that induce strong inhibitory signaling when Siglecs bind sialic acids. Hence, tumor cells use hyper sialic acid expression in their favor to modify the immune system that can lead to immune suppression. Such engagement along the Siglec-sialic acid axis can dampen major killing modes of effector immune cells and suppress the activation of immune responses, which can lead to immune tolerance and tumor growth. In this review, we emphasized recent studies on all 15 Siglecs found in humans, many of which still remain understudied. In addition, we highlighted different strategies in disrupting the surface Siglec-sialic acid interactions, including antibodies and glycan moieties, which can steer back antitumor immune responses to reduce tumor size and improve overall survival of cancer patients.Hypersialylation is a common post-translational modification of protein and lipids found on cancer cell surfaces, which participate in cell-cell interactions and in the regulation of immune responses. Sialic acids are a family of nine-carbon α-keto acids found at the outermost ends of glycans attached to cell surfaces. Given their locations on cell surfaces, tumor cells aberrantly overexpress sialic acids, which are recognized by Siglec receptors found on immune cells to mediate broad immunomodulatory signaling. Enhanced sialylation exposed on cancer cell surfaces is exemplified as “self-associated molecular pattern” (SAMP), which tricks Siglec receptors found on leukocytes to greatly down-regulate immune responsiveness, leading to tumor growth. In this review, we focused on all 15 human Siglecs (including Siglec XII), many of which still remain understudied. We also highlighted strategies that disrupt the course of Siglec-sialic acid interactions, such as antibody-based therapies and sialic acid mimetics leading to tumor cell depletion. Herein, we introduced the central roles of Siglecs in mediating pro-tumor immunity and discussed strategies that target these receptors, which could benefit improved cancer immunotherapy.
Highlights
Siglecs (Sialic acid-binding Immunoglobulin-like Lectins) might hold the key to better solutions for human diseases, including cancer
Tumor immune escape is a hallmark of tumor growth [1] and involves tumor expression of inhibitory immune checkpoints or “don’t eat me” signals such as programmed cell death ligand 1 (PD-L1), β2-microglobulin (β2 m), CD24, and CD47 to evade immune responses [2,3,4,5]
Several Siglec-directing Antibody Drug Conjugates (ADC) have been approved by the FDA for clinical use in haematological neoplasms including Inotuzumab ozogamicin (InO; Besponsa®; Pfizer; CMC-544) and Gemtuzumab ozogamicin (GO; Mylotarg; CMA-676; Wyeth Laboratories, Philadelphia, PA, USA), targeting CD22 and CD33 respectively (Figure 5C) [198,199]
Summary
Siglecs (Sialic acid-binding Immunoglobulin-like Lectins) might hold the key to better solutions for human diseases, including cancer. Siglecs as potential immune checkpoints are expressed on most white blood cells in the immune system (Figure 1) and bind to sialoglycans with variable binding preferences [9]. Sialic acid is not always needed for Siglec-ligand interaction, suggesting direct protein ligands [4]. Among the 15 human Siglecs, most Siglecs bear one or more cytosolic immune receptor tyrosine-based inhibitory motifs (ITIMs) to signal negatively to dampen immune response. As current cancer immunotherapy focuses on selected and upregulated targets instead of systemic activation of immune responses, we summarized the latest findings and strategies on human Siglecs as targets in cancer, which are immune normalization targets in glyco-immunology.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
